To confirm whether Sorafenib's anti‐tumor activity in ESCC depends specifically on TRIM21, we performed rescue experiments using both in vitro CCK‐8 proliferation assays and in vivo subcutaneous xenograft models. The gene discussed is TRIM21; the disease is neoplasm.